Evidence-based probiotic for Chronic Fatigue Syndrome

Projektinformationen

Help4ME

ID Finanzhilfevereinbarung: 867223

DOI

10.3030/867223

Projekt abgeschlossen

EK-Unterschriftsdatum 23 April 2019

Startdatum 1 April 2019

Enddatum 30 September 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

IMMUNEBIOTECH MEDICAL SWEDEN AB
Sweden

Periodic Reporting for period 1 - Help4ME (Evidence-based probiotic for Chronic Fatigue Syndrome)

Berichtszeitraum: 2019-04-01 bis 2019-09-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Let’s imagine being tired to the point where any activity causes weeks of weakness and pain. Common noises and daylight become an unbearable torture and a “brain fog” doesn’t let you think clearly. In spite of the tiredness, you wake up without
being refreshed, if you can fall asleep at all. Days pass as well as doctors check-ups, and no one is able to tell you what is wrong. Finally, after few years of trying to pull yourself up, the answer is Chronic Fatigue Syndrome (CFS). Happy of the fact
of being diagnosed, you quickly learn that it means that there are no measures able to cure you and chances of full recovery are only 5%. Indeed, the reality of CFS patients’ life is tough and contrary to many beliefs it is not a rare disease. The world count of diagnosed CFS is estimated for up to 24 million cases and considered to be only 10% of the whole CFS population. Although frequently triggered by infection, cause of CFS is not yet known. Researches look for its source in the guts, which
are inhabited by billions of microorganisms and form a complex ecosystem with profound impact on the whole body. Imbalance of gut microflora, damaged gut barrier functions and dysfunctional immune responses are known in CFS and
shared with another disease - Irritable Bowel Syndrome (IBS), which frequently accompany CFS. GutMagnific™ is an evidence-based probiotic scientifically designed and shown to be effective in correcting the gut microflora disbalance – a source of CFS and IBS symptoms. The novelty of the product lies in the unique combination of 5 lactobacilli strains with evidence-based efficacy and shows a life-changing promise to severely underserved population of CFS patients.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The project has delivered a business plan for the clinical validation and launch of GutMagnific™.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The disruptiveness of GutMagnific is its efficacy as a result of the company's evidence-based design of strain combination, addressing gastrointestinal hallmarks of CFS (dysbiosis, gut permeability and inflammation). The high degree of novelty of GutMagnific is further expressed in the fact that it establishes a completely new category of probiotics - a multi-targeting solution, scientifically designed for optimal therapeutic effect, using similar methods as in traditional drug discovery, focused on the interplay between the microbiome, the immune system and intestinal barrier.

Company logo